NeoGenomics (NEO)

Executive Summary

NeoGenomics is a leading precision oncology diagnostics company offering comprehensive cancer testing services, including next-generation sequencing (NGS), liquid biopsy, and traditional modalities. With a database of over 2 million patient profiles, the company provides critical genomic insights to healthcare providers and biopharmaceutical partners, enabling personalized treatment decisions and real-world evidence generation. Headquartered in Fort Myers, Florida, NeoGenomics has established itself as a key player in the rapidly growing precision medicine market, supported by its multi-modal testing platform and expansive data assets. The company's strategic focus on expanding liquid biopsy capabilities and deepening partnerships with biopharma firms positions it for sustained growth. NeoGenomics continues to benefit from the increasing adoption of genomic testing in oncology, driven by regulatory tailwinds and clinical guidelines emphasizing comprehensive molecular profiling. While facing competition from peers, its unique combination of scale, data repository, and service breadth provides a competitive moat. Near-term performance will be influenced by test volume recovery, operational efficiency improvements, and success in commercializing new assays.

Upcoming Catalysts (preview)

• Q3 2026Launch of Comprehensive Liquid Biopsy Assay75% success
• Q2 2026Biopharma Partnership for Real-World Data Solutions80% success
• TBDFDA Approval for Companion Diagnostic Test60% success